Literature DB >> 10837957

Phase II trial of adjuvant radiation and intraperitoneal 5-fluorouracil for locally advanced colon cancer: results with 10-year follow-up.

J A Palermo1, F Richards, K K Lohman, J V Lovelace, J Atkinson, L D Case, D R White, A W Blackstock.   

Abstract

PURPOSE: To determine the toxicity, disease-free survival, and overall survival for patients with Modified Astler-Coller (MAC) B2-3 or C1-3 colon cancer receiving adjuvant radiation and sequential intraperitoneal 5-fluorouracil (5-FU). METHODS AND MATERIALS: From August 1984 to June 1989, 45 patients were accrued to this Phase II trial and received a 21-week course of intraperitoneal 5-FU (20 mg/kg/d x 5) and external beam radiation. The radiation was delivered to the tumor bed and para-aortic lymph nodes in two split-courses of 22.5 Gy, alternating with the first two cycles of chemotherapy. All patients then received 4 additional cycles of intraperitoneal 5-FU.
RESULTS: The therapy was well tolerated with 4 patients experiencing Grade 3 peritonitis. Four patients developed small bowel obstruction requiring surgery; in each instance, recurrent tumor was found at the time of laparotomy. The median and overall survivals at 10 years were 9.3 months and 53% respectively. Local failures were infrequent, occurring in only 11% of patients treated.
CONCLUSIONS: Sequential intraperitoneal 5-FU and tumor-bed/para-aortic irradiation is tolerable in patients with resected colon cancer. Although the incidence of local and regional relapse appeared to be lower than anticipated, this did not appear to translate into improved survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837957     DOI: 10.1016/s0360-3016(00)00474-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  4 in total

1.  Adjuvant intraperitoneal chemotherapy for the treatment of colorectal cancer at risk for peritoneal carcinomatosis: a systematic review.

Authors:  Paul L Feingold; Nicholas D Klemen; Mei Li M Kwong; Barry Hashimoto; Udo Rudloff
Journal:  Int J Hyperthermia       Date:  2017-12-07       Impact factor: 3.914

2.  Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colon cancer at high risk of peritoneal carcinomatosis; the COLOPEC randomized multicentre trial.

Authors:  Charlotte E L Klaver; Gijsbert D Musters; Willem A Bemelman; Cornelis J A Punt; Victor J Verwaal; Marcel G W Dijkgraaf; Arend G J Aalbers; Jarmila D W van der Bilt; Djamila Boerma; Andre J A Bremers; Jacobus W A Burger; Christianne J Buskens; Pauline Evers; Robert J van Ginkel; Wilhelmina M U van Grevenstein; Patrick H J Hemmer; Ignace H J T de Hingh; Laureen A Lammers; Barbara L van Leeuwen; Wilhelmus J H J Meijerink; Simon W Nienhuijs; Jolien Pon; Sandra A Radema; Bert van Ramshorst; Petur Snaebjornsson; Jurriaan B Tuynman; Elisabeth A Te Velde; Marinus J Wiezer; Johannes H W de Wilt; Pieter J Tanis
Journal:  BMC Cancer       Date:  2015-05-24       Impact factor: 4.430

Review 3.  Intraperitoneal chemotherapy as adjuvant treatment to prevent peritoneal carcinomatosis of colorectal cancer origin: a systematic review.

Authors:  D A M Sloothaak; B Mirck; C J A Punt; W A Bemelman; J D W van der Bilt; A D'Hoore; P J Tanis
Journal:  Br J Cancer       Date:  2014-07-15       Impact factor: 7.640

4.  Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study - protocol for a randomised, multicentre, phase 3 trial.

Authors:  Fabio Pacelli; Chiara Gerardi; Eliana Rulli; Carlo Abatini; Stefano Rotolo; Silvio Garattini; Gianluigi Melotti; Valter Torri; Fabio Galli; Erica Rulli; Andrea Di Giorgio
Journal:  BMJ Open       Date:  2022-08-01       Impact factor: 3.006

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.